Menu Back toSession 8 Track 1: IDMP Ontology: Semantic Interoperability Throughout the Entire Medicinal Product Lifecycle

Regulatory Submissions, Information, and Document Management Forum

Session 8 Track 1: IDMP Ontology: Semantic Interoperability Throughout the Entire Medicinal Product Lifecycle

Session Chair(s)

Michiel Stam

Michiel Stam

  • Director Regulatory Information Management
  • Qdossier - A Celegence Company, Netherlands
This session will introduce the IDMP Ontology initiative of Bayer, Boehringer Ingelheim, GSK, J&J, Merck KGaA, Novartis and Roche, coming together at Pistoia Alliance Pistoia Alliance’s IDMP Ontology project. It will provide an outline of the implementation challenges of ISO IDMP standards at pharma companies and showcase how an ontology can help achieve semantic interoperability of product data. The IDMP Ontology augments the existing conceptual models defined in ISO IDMP standards, provides concise formal definitions and enables deep, semantic interoperability based on FAIR data principles.
Learning Objective : At the conclusion of this session, participants should be able to:
  • Understand the value of the standardized ISO IDMP Logical Model applying FAIR data principles and semantic web technologies
  • Apply presented implementation guidelines to increase IDMP adoption success
  • Learn how to become a contributor that can shape further development of IDMP Ontology

Speaker(s)

Rafail Kasapis, MSc

Semantic Interoperability Throughout the Entire Medicinal Product Lifecycle with IDMP Ontology

Rafail Kasapis, MSc

  • Seior Data Governance and Strategy Consultant
  • OSTHUS, Germany
Heiner Oberkampf, PhD

A Data-Centric Implementation of IDMP in Regulatory and Connected Functions with the IDMP Ontology

Heiner Oberkampf, PhD

  • CEO and Co-Founder
  • ACCURIDS, Germany
Sheila Elz, MA, MSc

Broader Industry Initiatives and Benefits of IDMP for Pharma Companies

Sheila Elz, MA, MSc

  • Master Data Manager
  • Bayer, Germany